# IntraLase Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/intralase

- Industry: Medical Devices & Equipment
- Headquarters: Irvine, US
- Website: www.intralasefacts.com
- Total disclosed funding: $7.5M
- Latest round: Series G (May 1, 2002)
- Investors on record: 2

## About

IntraLase Corporation specializes in advanced laser technology for ophthalmic procedures, particularly in the realm of vision correction. Their innovative solutions enhance surgical precision and patient outcomes in the treatment of refractive vision errors.IntraLase Corporation, founded in 1997 and headquartered in Irvine, US, develops excimer laser technology for LASIK eye surgeries. The company experienced a significant strategic shift when it was acquired by Abbott Laboratories for USD 808 mn in April 2007, marking a pivotal moment in its history. This acquisition followed a series of 5 deals that underscored the company's growth trajectory.IntraLase Corporation offers a suite of laser-assisted surgical technologies designed to improve the quality and safety of vision correction procedures. Their flagship product, the IntraLase iFS laser system, provides unparalleled precision in creating corneal flaps, which is crucial for LASIK surgeries. The company serves a global market including North America and Europe, catering to a range of clients from individual surgeons to large ophthalmic practices.IntraLase Corporation's revenue model primarily consists of sales from its advanced laser systems and ongoing service agreements with clients. Revenue is generated through the sale of equipment, as well as maintenance and support contracts, which ensures a continuous revenue stream.Following its acquisition by Abbott Laboratories, IntraLase Corporation is aligned with Abbott's strategic vision for expanding into new markets. The company plans to enhance its product offerings with the development of next-generation laser systems aimed at improving surgical outcomes. The funding from the acquisition will support research and development initiatives, thereby facilitating the launch of innovative products in the ophthalmic market by 2025.

## Funding rounds

- Series G, May 1, 2002 — Meritech Capital Partners
- Series C, Sep 23, 1999, $7.5M — Brentwood Venture Capital

## Investors

- Brentwood Venture Capital (https://capitalatlas.ai/funds/brentwood-venture-capital) — Series C
- Meritech Capital Partners (https://capitalatlas.ai/funds/meritech-capital-partners) — Series G